Literature DB >> 18997159

The appropriateness of routine medication treatment for schizophrenia.

Alexander S Young1, Noosha Niv, Amy N Cohen, Christopher Kessler, Kirk McNagny.   

Abstract

OBJECTIVE: Although national guidelines specify appropriate strategies for the treatment of schizophrenia, this disorder presents challenges to clinicians and health-care organizations. To improve care, it is useful to understand how often patients receive appropriate treatment. Most research evaluating treatment was performed when first-generation antipsychotic medications were the modal treatment. Given that most prescriptions are now for second-generation medications, this study describes current clinical problems and the appropriateness of treatment in routine practice.
METHOD: Between 2002 and 2004, a random sample of patients (n = 398) were interviewed at baseline and 1 year at 3 Department of Veterans Affairs mental health clinics. Symptoms and side effects were assessed. Analyses examined whether prescribing were consistent with guidelines in patients with significant psychosis, depression, parkinsonism, akathisia, tardive dyskinesia, or elevated weight.
RESULTS: Few patients met criteria for depression, parkinsonism, or akathisia. A total of 44% of patients had significant psychosis, 11% had tardive dyskinesia, and 46% were overweight. Medication was appropriate in 27% of patients with psychosis, 25% of patients with tardive dyskinesia, and 2% of patients with elevated weight. Management of elevated weight improved modestly over time. Treatment was more likely to improve for patients whose psychiatrists had more than 12 patients with schizophrenia in their caseload.
CONCLUSION: Compared with the 1990s, outpatients are more likely to have significant psychosis. The rate of appropriate treatment of psychosis is unchanged. Weight gain has become a prevalent side effect, yet treatment is rarely changed in response to weight. There is a need for interventions that improve management of psychosis and weight.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18997159      PMCID: PMC2894584          DOI: 10.1093/schbul/sbn138

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  48 in total

1.  Mood stabilization and weight loss with topiramate.

Authors:  A Gordon; L H Price
Journal:  Am J Psychiatry       Date:  1999-06       Impact factor: 18.112

Review 2.  World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.

Authors:  Rajiv Tandon; R H Belmaker; Wagner F Gattaz; Juan J Lopez-Ibor; Ahmed Okasha; Bruce Singh; Dan J Stein; Jean-Pierre Olie; W Wolfang Fleischhacker; Hans-Juergen Moeller
Journal:  Schizophr Res       Date:  2008-02-19       Impact factor: 4.939

3.  Bed closures and incarceration rates among users of Veterans Affairs mental health services.

Authors:  R A Rosenheck; S Banks; J Pandiani; R Hoff
Journal:  Psychiatr Serv       Date:  2000-10       Impact factor: 3.084

4.  Training and quality assurance with the Structured Clinical Interview for DSM-IV (SCID-I/P).

Authors:  J Ventura; R P Liberman; M F Green; A Shaner; J Mintz
Journal:  Psychiatry Res       Date:  1998-06-15       Impact factor: 3.222

5.  The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003.

Authors:  Anthony F Lehman; Julie Kreyenbuhl; Robert W Buchanan; Faith B Dickerson; Lisa B Dixon; Richard Goldberg; Lisa D Green-Paden; Wendy N Tenhula; Daniela Boerescu; Cenk Tek; Neil Sandson; Donald M Steinwachs
Journal:  Schizophr Bull       Date:  2004       Impact factor: 9.306

6.  A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.

Authors:  John W Newcomer; Joao Alberto Campos; Ronald N Marcus; Christopher Breder; Robert M Berman; Wendy Kerselaers; Gilbert J L'italien; Marleen Nys; William H Carson; Robert D McQuade
Journal:  J Clin Psychiatry       Date:  2008-07       Impact factor: 4.384

7.  Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission.

Authors:  Marcia Valenstein; Laurel A Copeland; Frederic C Blow; John F McCarthy; John E Zeber; Leah Gillon; C Raymond Bingham; Thomas Stavenger
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

8.  Measuring the quality of outpatient treatment for schizophrenia.

Authors:  A S Young; G Sullivan; M A Burnam; R H Brook
Journal:  Arch Gen Psychiatry       Date:  1998-07

9.  Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.

Authors:  M H Davidson; J Hauptman; M DiGirolamo; J P Foreyt; C H Halsted; D Heber; D C Heimburger; C P Lucas; D C Robbins; J Chung; S B Heymsfield
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272

10.  EQUIP: implementing chronic care principles and applying formative evaluation methods to improve care for schizophrenia: QUERI Series.

Authors:  Alison H Brown; Amy N Cohen; Matthew J Chinman; Christopher Kessler; Alexander S Young
Journal:  Implement Sci       Date:  2008-02-15       Impact factor: 7.327

View more
  5 in total

1.  Implementing Patient-Reported Outcomes to Improve the Quality of Care for Weight of Patients with Schizophrenia.

Authors:  Alexander S Young; Amy N Cohen; Alison B Hamilton; Gerhard Hellemann; Christopher Reist; Fiona Whelan
Journal:  J Behav Health Serv Res       Date:  2019-01       Impact factor: 1.505

2.  Psychoeducation Improves Compliance and Outcome in Schizophrenia Without an Increase of Adverse Side Effects: A 7-Year Follow-up of the Munich PIP-Study.

Authors:  Josef Bäuml; Gabriele Pitschel-Walz; Anja Volz; Sandra Lüscher; Michael Rentrop; Werner Kissling; Thomas Jahn
Journal:  Schizophr Bull       Date:  2016-03-08       Impact factor: 9.306

3.  Unmet need for mental health care in schizophrenia: an overview of literature and new data from a first-admission study.

Authors:  Ramin Mojtabai; Laura Fochtmann; Su-Wei Chang; Roman Kotov; Thomas J Craig; Evelyn Bromet
Journal:  Schizophr Bull       Date:  2009-06-08       Impact factor: 9.306

4.  Passive Mobile Self-tracking of Mental Health by Veterans With Serious Mental Illness: Protocol for a User-Centered Design and Prospective Cohort Study.

Authors:  Alexander S Young; Abigail Choi; Shay Cannedy; Lauren Hoffmann; Lionel Levine; Li-Jung Liang; Melissa Medich; Rebecca Oberman; Tanya T Olmos-Ochoa
Journal:  JMIR Res Protoc       Date:  2022-08-05

5.  Monitoring and managing metabolic effects of antipsychotics: a cluster randomized trial of an intervention combining evidence-based quality improvement and external facilitation.

Authors:  Richard R Owen; Karen L Drummond; Kristen M Viverito; Kathy Marchant; Sandra K Pope; Jeffrey L Smith; Reid D Landes
Journal:  Implement Sci       Date:  2013-10-08       Impact factor: 7.327

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.